Shop
Showing 391–420 of 429 results
-
SMESyntekabio
Developing treatments for refractory and rare diseases based on the development of various healthcare platforms through analysis of disease and compound big data
-
SMET&R Biofab
-
LargeTaegeuk Pharmaceutical Co., Ltd
Specialty pharmaceutical company in ophthalmology, radiology, and gastroenterology
-
LargeTaejoon Pharm. Co., Ltd
Drugs to cover various therapeutic areas such as mydriatics, cry eye, anti-allergy, local anesthetics, diagnostics, iodin contrast media, and more
-
GlobalTakeda Pharmaceuticals Korea Co., Ltd.
Patient-focused, R&D-driven global biopharmaceutical company
-
-
DiagnosticsTASCOM (YidoBio)
TASCOM (YidoBio)’s R&D Center focuses on developing cell therapy for the treatment of diabetes with leading scientists working with key doctors in the field. TASCOM (YidoBio) also distributes diabetic and related medical supplies from top manufacturers such as BD, Arkray, and i-SENS.
-
-
SMETegoscience
Developing pipelines in regenerative medicine, stem cell, and alternative testing spaces
-
-
VentureTHERABEST
RNK™ (mRNA based NK cell) is an autologous CAR-NK cell therapy platform that introduces mRNA technology to NK cell mass expansion.
EiNK™ (Enhanced iPSC-derived NK cell) is an allogeneic CAR-NK cell therapy platform in which non-viral gene editing technology is used in iPSCs prior to NK cell differentiation. -
-
-
VentureTiCARos
TiCARos proposes a new treatment option using cutting-edge technology in immunology and antibody-engineering. TiCARos develops best-in class, first-in class therapies based on Converter CAR platform for better T cell activity and on CLIP CAR platform for more stable immune synapse of CAR-T cells.
-
-
VentureTSD Life Science
-
-
-
-
VentureVaxcell Bio Therapeutics
Vaxcell-bio aims for fundamental chemotherapy that encompasses all components of the immune system
-
VentureVigenCell
VIGENCELL is a company that focuses on the development of drugs using nano platform technology.
-
-
-
VentureVoronoi
Voronoi is a biotech company that develops novel kinase inhibitors and target protein degraders. They have about 120 employees, each specialized in Synthesis/Structural Biology, Biology, and AI/Molecular Modeling, etc, who have great expertise in kinase inhibitors.
-
VentureVT Bio (GMP Bio)
Established in July 2000, a drug development research company on next-generation cell therapy and natural products through links to industry-academic associations and a number of national projects.
-
VentureWellmarker Bio
Wellmarker Bio is a company that has developed biomarker-based cancer drugs based on accumulated developmental experience and know-how. They have a new drug development institute including synthetic and bio-research and management support center. Utilizing R&D infrastructure from Asan Medical Center in Seoul Republic of Korea they are focusing on developing new cancer drugs.
-
-
-
-